The Clinical Research Program at the Cardiovascular Institute allows our physicians to participate in national studies which provide current data to enhance treatment protocols for cardiovascular issues.
Of course, we could not participate without our patients who volunteer to be a part of a clinical trial or registry. Through our participation, select patients may have access to new technologies or medical therapies that are not yet widely available. However, many studies are simply observational and collect data on how patients respond to various therapies that are already the standard of care, to determine where improvements may be needed. No matter what type of research, it is our patients’ participation that provides the necessary data to make advancements in cardiovascular treatment.
The selection criteria for each study are very specific.
Most patients will not be asked to participate in research. Patients who are considered a good candidate for a certain study, and are approached about participating, are under no obligation to enroll. Your cardiologist and our research coordinator will provide you with comprehensive information to make an informed decision on your study participation and treatment options. Patients who participate in studies are monitored, most commonly through follow-up appointments, for a prescribed amount of time per the study requirements. Patients are asked to please consider their long term commitment to attend all follow-up appointments as part of their participation. While patients can certainly choose to remove themselves from a study, it is our hope that those who choose to enroll will work with us to complete their participation.
At Cardiovascular Institute, we believe that our participation in clinical research gives us access to new data and information that continually improves the quality of care we provide to all of our patients. We’re proud to bring this level of commitment to treating cardiovascular disease to our community.
If you have any questions regarding your eligibility for studies that Cardiovascular Institute is currently participating in you may contact our research coordinator:
Shelley Sherk at (850)769-0329
Links to trials actively enrolling at Cardiovascular Institute of Northwest Florida
VITAL-HF
The purpose of this study is to evaluate if a remote, digital study intervention by Story Health that helps clinicians use and optimally adjust heart failure medications is safe and effective. This web-based digital study intervention used on your smart phone will be compared to usual heart failure care, including medication use and adjustment, in participants with heart failure with reduced ejection fraction (HFrEF). Please refer to this flyer for more information.
Principal Investigator at CVI: Amir Haghighat, M.D.
FSU Heart Failure Study for Veterans
CVI has the privilege of working with Dr. Lucinda Graven at the Florida State University College of Nursing to help U.S. Veterans manage their heart failure from home through telephone-based sessions.
Please refer to this flyer for more information.
Principal Investigator at CVI: Ajay Mhatre, M.D.
CREST 2
CAROTID REVASCULARIZATION AND MEDICAL MANAGEMENT FOR ASYMPTOMATIC CAROTID STENOSIS TRIAL
In addition, to view a short video explanation of the objectives of this trial and to learn who may be a candidate visit crest2trial.org
Principal Investigator: Amir Haghighat, M.D.
CREST-2 REGISTRY
The objective of C2R is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial (clinicaltrials.gov ID NCT02089217). Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with carotid artery stenting (CAS) performed by experienced and skilled interventionists. Interventionists’ eligibility will be determined by a multi-specialty Interventional Management Committee (IMC). Patient eligibility will include patients with standard or high-risk, symptomatic or asymptomatic carotid artery disease. Patients will be followed for the occurrence of post-procedural complications. The primary safety and quality endpoint will be the occurrence of any stroke or death within the 30-day period following the stenting procedure.
https://clinicaltrials.gov/ct2/show/NCT02240862?term=crest+2&draw=2&rank=1
Principal Investigator: Amir Haghighat, M.D.
MEDTRONIC PRODUCT SURVEILLANCE REGISTRY
Patients who receive a Medtronic device may qualify for this registry. Please see the patient brochure for more information. Click here to view brochure.
Principal Investigator: Nghia Hoang, D.O.